Vir Biotechnology, Inc.

Alnylam Pharmaceuticals, Inc.

Florian A Lempp

Akin Akinc

Davide Corti

Mark K Schlegel

James D McIninch

Gyorgy Pal Snell

Martina Beltramello

Elisabetta Cameroni

Dora Pinto

Yesseinia Anglero-Rodriguez

Amalio Telenti

Christy M Hebner

Katja Fink

Gyorgy Snell

The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.

Coronavirus IRNA compositions and methods of use thereof

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.

Antibodies against SARS-CoV-2 and methods of using the same

Coronavirus iRNA compositions and methods of use thereof

Growing community of inventors

San Francisco, CA, United States of America

Florian A Lempp